CMPS

#1736
COMPASS Pathways Plc - American Depository Shares
13.0 6 USD
+9.56%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
13.06
13.06
년간 변동
0.12
13.06
일일 변동
+9.56%
월간 변동
+54.37%
6달 변화
+138.32%
년간 변동율
+105.02%
이전 종가
11.9 2
Open
13.0 6
저가
13.0 6
High
13.0 6
양
59
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 1.76 B
  • Employee 156
  • Founded 2016
  • CEO N/A
  • Website compasspathways.com
  • Headquarter United Kingdom
  • FIGI BBG00X0VY2N1
  • Industry 의료 기관
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-1.76
주가매출액비율
622.4

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

뉴스